On February 18, 2020 Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, reported that its Director of Strategy and Business Development, Dr. Jingyi Xiang, will be presenting at CAR-TCR Summit Europe being held at the Novotel London West, London, United Kingdom on February 25, 2020 (Press release, Eureka Therapeutics, FEB 18, 2020, View Source [SID1234554450]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Title:

Novel Antibody-TCR Platform (ARTEMIS T cells) Combines Fab-based Antigen Recognition with gamma/delta-TCR Signalling for Favorable Safety and Efficacy Profile in T Cell Immunotherapy

Speaker:

Dr. Jingyi Xiang

Event Program:

Translation Track

Date:

Tuesday, February 25, 2020

Time:

5:30 p.m. GMT